On December 23, 2025, the U.S. Food and Drug Administration granted approval to Novo Nordisk’s oral Wegovy pill, marking the first oral semaglutide product cleared for chronic weight management. This milestone triggered a 7% rally in Novo Nordisk’s shares on the day of the announcement, reversing much of the -40% total return recorded in 2025 through December 30. The approval positions Novo Nordisk to commence U.S. sales in January 2026, several months ahead of oral weight-loss rival products, and underscores management’s strategy to diversify administration routes beyond injectables.

Novo Nordisk’s January launch gives it a lead over Eli Lilly’s orforglipron, which is not expected to receive FDA clearance until late March 2026. In clinical trials, oral Wegovy delivered an average 16.6% weight loss at 64 weeks among adherent patients, compared with Lilly’s 12.4% mean reduction at 72 weeks. After adjusting for placebo response and treatment discontinuation, oral Wegovy still maintained a roughly 2.1 percentage‐point advantage, translating into a potential preference among physicians and patients seeking faster results within a key treatment window.

Novo Nordisk’s oral semaglutide launch is critical to reaccelerating top‐line growth following Q3 2025 sales expansion of just 5%, down from 21% a year earlier. Investors will closely monitor initial pill uptake and market share gains in the oral GLP-1 segment to gauge whether Novo can stem Lilly’s lead in the broader incretin analogs market, where tirzepatide drove a 54% sales surge at Lilly during the same quarter. Beyond oral Wegovy, the late-stage pipeline includes CagriSema, which achieved 22.7% mean weight loss at 68 weeks, offering further upside potential if approved and commercialized successfully.